Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Françoise Descotes

Showing results (11-20 of 55) with videos related to

Pageof 6
Sort By:
Plos One|May 16, 2014
Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancersMarion David, Debashish Sahay, Florence Mege, et al.
Gynecologic Oncology|April 23, 2020
Transcriptome profiling of gastric-type endocervical adenocarcinomas identifies key signaling pathways for tumor progressionDamien Vasseur, Jonathan Lopez, Sabrina Croce, et al.
International Journal of Oncology|December 28, 2011
Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesisMarion David, Johnny Ribeiro, Françoise Descotes, et al.
The American Journal of Dermatopathology|July 4, 2020
Lipofibromatosis-Like Neural Tumor: A Case Report and Review of the LiteratureLaura Crumbach, Françoise Descotes, Pierre-Paul Bringuier, et al.
Urology|March 9, 2010
Quantitative loss of heterozygosity analysis for urothelial carcinoma detection and prognosisDelphine Collin-Chavagnac, Christophe Marçais, Stephane Billon, et al.
Annales De Pathologie|November 9, 2010
[Microsatellite markers and methylation of promoters of tumour suppressor genes in bladder cancer]Delphine Collin-Chavagnac, Françoise Descotes, Stéphane Billon, et al.
European Journal of Endocrinology|May 31, 2025
From hyperplasia to carcinoma: a molecular driven adrenal diseaseElisa Dybal, Myriam Decaussin-Petrucci, Françoise Descotes, et al.
Clinical Breast Cancer|July 16, 2008
Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activatorFrançoise Descotes, Benjamin Riche, Simone Saez, et al.
The Journal of Steroid Biochemistry and Molecular Biology|June 14, 2005
Divergent biological effects of estradiol and diethylstilbestrol in the prostate cancer cell line MOPJean-Jacques Kalach, Marie-Odile Joly-Pharaboz, Jacqueline Chantepie, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2022
Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitorsLola Paulet, Alexis Trecourt, Alexandra Leary, et al.
Pageof 6

Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Plos One|May 16, 2014
Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancersMarion David, Debashish Sahay, Florence Mege, et al.
Gynecologic Oncology|April 23, 2020
Transcriptome profiling of gastric-type endocervical adenocarcinomas identifies key signaling pathways for tumor progressionDamien Vasseur, Jonathan Lopez, Sabrina Croce, et al.
International Journal of Oncology|December 28, 2011
Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesisMarion David, Johnny Ribeiro, Françoise Descotes, et al.
The American Journal of Dermatopathology|July 4, 2020
Lipofibromatosis-Like Neural Tumor: A Case Report and Review of the LiteratureLaura Crumbach, Françoise Descotes, Pierre-Paul Bringuier, et al.
Urology|March 9, 2010
Quantitative loss of heterozygosity analysis for urothelial carcinoma detection and prognosisDelphine Collin-Chavagnac, Christophe Marçais, Stephane Billon, et al.
Annales De Pathologie|November 9, 2010
[Microsatellite markers and methylation of promoters of tumour suppressor genes in bladder cancer]Delphine Collin-Chavagnac, Françoise Descotes, Stéphane Billon, et al.
European Journal of Endocrinology|May 31, 2025
From hyperplasia to carcinoma: a molecular driven adrenal diseaseElisa Dybal, Myriam Decaussin-Petrucci, Françoise Descotes, et al.
Clinical Breast Cancer|July 16, 2008
Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activatorFrançoise Descotes, Benjamin Riche, Simone Saez, et al.
The Journal of Steroid Biochemistry and Molecular Biology|June 14, 2005
Divergent biological effects of estradiol and diethylstilbestrol in the prostate cancer cell line MOPJean-Jacques Kalach, Marie-Odile Joly-Pharaboz, Jacqueline Chantepie, et al.
European Journal of Cancer (Oxford, England : 1990)|March 13, 2022
Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitorsLola Paulet, Alexis Trecourt, Alexandra Leary, et al.
Pageof 6